The JAMP Pharma Group, a leader in the Canadian pharmaceutical industry, announces the launch of PrJAMP Enzalutamide ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month) enzalutamide (Xtandi) monotherapy for patients with biochemically ...

Pharmacokinetic analysis revealed sustained activity at 15 days, a finding corroborated by imaging that demonstrated ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and ...

Its Oncology segment comprises around 27% of total revenues and 42% of its Innovative Medicine segment sales. Its oncology sales rose 20.9% on an operational basis in 2025, driven by strong market ...

Kyntra Bio Inc. KYNB, formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide for treating ...

Astellas Pharma has awarded its healthcare provider (HCP) and direct-to-consumer (DTC) business to CMI Media Group, Compas ...

Pfizer PFE faces several near-term challenges like declining COVID sales, the upcoming loss of exclusivity (“LOE”) cliff and U.S. Medicare Part D headwinds. These headwinds can hurt its sales and ...